logo

Bristol-Myers Squibb Co. (BMY)



Trade BMY now with
  Date
  Headline
10/17/2018 7:01:15 AM Bristol-Myers Squibb Says 28 Abstracts Related To ORENCIA To Be Presented At ACR/ARHP Annual Meeting
10/11/2018 7:00:08 AM Bristol-Myers Squibb, Compugen Enter Clinical Trial Collaboration To Evaluate COM701 In Combination With Opdivo
9/18/2018 7:00:11 AM EMA Validates Bristol-Myers Squibb’s Application For Empliciti Plus Pomalidomide And Low-Dose Dexamethasone
9/12/2018 4:13:46 PM Bristol-Myers Squibb Declares Quarterly Dividend Of $0.40, Payable Nov. 1/ Record Oct. 5
9/12/2018 4:13:09 PM Bristol-Myers Squibb Co. (BMY) Declares Quarterly Dividend of $ 0.40, Record Date 10/5/2018
9/12/2018 2:05:13 AM Bristol-Myers Reports Results From Phase 2 Study Of BMS-986165, Oral, Selective Tyrosine Kinase 2 Inhibitor
8/30/2018 7:00:17 AM FDA Accepts Bristol-Myers Squibb’s Application For Sprycel
8/28/2018 9:04:27 AM Bristol-Myers Squibb Appoints Christopher Boerner As EVP And Chief Commercial Officer
8/23/2018 7:02:36 AM FDA Accepts For Priority Review Bristol-Myers Squibb’s Application For Empliciti + Pomalidomide & Low-Dose Dexamethasone
8/17/2018 6:59:49 AM Bristol-Myers Squibb Says FDA Approves Opdivo As New Medication For Certain Patients With Previously Treated SCLC
7/31/2018 7:03:38 AM European Commission Approves Bristol-Myers Squibb’s Opdivo